- Fund Type: Open-End Fund
- Objective: Govt/Agency-Short Term
- Asset Class: Debt
- Geographic Focus: Mexico
+Tasa SA de CV SIID
+ Add to WatchlistTASAF1:MM
0.91 MXN 0.000.00%As of 09:29:30 ET on 06/18/2013.
Snapshot for +Tasa SA de CV SIID (TASAF1)
| Year To Date: | +0.12% | 3-Month: | +0.07% | 3-Year: | +0.29% | 52-Week Range: | 0.90 - 0.91 |
|---|---|---|---|---|---|---|---|
| 1-Month: | +0.03% | 1-Year: | +0.27% | 5-Year: | +0.72% | Beta vs FCOMPAN: | 0.33 |
Fund Profile & Information for TASAF1
+Tasa SA de CV SIID is an open-end fund incorporated in Mexico. The Fund's objective is capital appreciation. The Fund primarily invests 60% of its assets in government fixed-income securities.
| Inception Date: | 09-07-1999 | Telephone: | 52-55-5033-3333 |
|---|---|---|---|
| Managers: | JORGE CAMPERO | ||
| Web Site: | www.intercam.com.mx/ | ||
Fundamentals for TASAF1
| NAV | (on 2013-06-18) 0.91 |
|---|---|
| Assets (M) | (on 2013-05-31) 2,058.53 |
| Fund Leveraged | N |
| Minimum Investment | 1,000.00 |
| Minimum Subsequent Investment | - |
Dividends for TASAF1
No dividends reported
Fees & Expenses for TASAF1
| Front Load | 0.00 |
|---|---|
| Back Load | 0.00 |
| Current Mgmt Fee | 1.07 |
| Redemption Fee | 0.00 |
| 12b1 Fee | - |
| Expense Ratio | - |
Top Fund Holdings for TASAF1
Filing Date: 04/30/2013| Name | Position | Value | % of Total |
|---|---|---|---|
| MBOND Float 06/28/18 | 4,707,554 | 467,097,739 | 24.527% |
| MBPA Float 10/05/17 | 3,178,641 | 317,400,698 | 16.667% |
| MBOND Float 08/13/15 | 3,009,817 | 300,067,318 | 15.756% |
| MBOND Float 02/15/18 | 2,888,344 | 286,415,893 | 15.040% |
| MBONO 6 ¼ 06/16/16 | 1,700,760 | 184,912,480 | 9.710% |
| MBONO 8 06/11/20 | 1,454,686 | 182,324,365 | 9.574% |
| MBOND Float 09/01/16 | 1,655,177 | 166,201,814 | 8.727% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page